source
- AbbVie signs up to $757M deal with Beijing's Brise Pharma for two preclinical migraine candidatesAbbVie announced a discovery and commercialization agreement with Brise Pharma, a Beijing-based biotech company. The partnership covers two preclinical migraine programs and is valued at up to $75…
- Teva halts phase 2 trial of emrusolmin for multiple system atrophy after futility analysisTeva Pharmaceuticals announced it is stopping a phase 2 study of its experimental small‑molecule drug emrusolmin, which was being tested in patients with the rare neurodegenerative condition multip…